Coya Therapeutics (NASDAQ:COYA – Get Free Report) and Spero Therapeutics (NASDAQ:SPRO – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership. Volatility and Risk Coya Therapeutics has a […]
Cantor Fitzgerald reissued their overweight rating on shares of Spero Therapeutics (NASDAQ:SPRO – Free Report) in a report published on Monday morning, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Spero Therapeutics’ FY2024 earnings at ($0.85) EPS. Separately, HC Wainwright restated a buy rating and set a $7.00 price objective on shares of Spero Therapeutics […]
With global staffing issues and the supply situation gradually improving, Boston Scientific's (BSX) international business is expected to have improved further in the third quarter.